# Biotech Daily Digest — 2025-12-19

**39 items from 4 sources**

## Summary by Source

- Endpoints News: 11 items
- Fierce Biotech: 11 items
- MHRA – News: 2 items
- arXiv q-bio: 15 items


## Endpoints News

- **[Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration](https://endpoints.news/joe-jimenezs-aditum-goes-to-fosun-for-major-biobuck-loaded-collaboration/)**  
  _Fri, 19 Dec 2025 13:15:31 +0000_  
  Aditum Bio, the biotech company creation firm from former Novartis leaders Joe Jimenez and Mark Fishman, has returned to China for another deal.

 This time, Aditum is forming a new company called ...

- **[Endpoints at JPM 2026: What we'll be talking about](https://endpoints.news/endpoints-at-jpm-2026-what-well-be-talking-about/)**  
  _Fri, 19 Dec 2025 12:00:27 +0000_  
  We’re a bit less than a month out from the JP Morgan meeting, where we'll host our own event on Monday and Tuesday that week in San Francisco.

 Every year is a ...

- **[Novo obesity partner nabs Pfizer vet as CBO; CureVac's leadership clears out as BioNTech takes over](https://endpoints.news/novo-obesity-partner-nabs-pfizer-vet-as-cbo-curevacs-leadership-clears-out-as-biontech-takes-over/)**  
  _Fri, 19 Dec 2025 12:00:17 +0000_  
  This is our final Peer Review in 2025. Thank you for reading the latest comings and goings for another year. Enjoy the holidays, and we’ll see you again on Jan. 9!



 → Kathy  ...

- **[US commission urges action as China's biotech sector advances](https://endpoints.news/us-commission-urges-action-as-chinas-biotech-sector-advances/)**  
  _Fri, 19 Dec 2025 05:01:37 +0000_  
  A US congressional commission is escalating its warning that the US could soon be eclipsed by China in biotech, after lawmakers took up some of its recommendations earlier this year.

 In a report released early ...

- **[Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths](https://endpoints.news/daiichi-and-mercks-i-dxd-lung-cancer-study-faces-partial-hold-due-to-deaths/)**  
  _Thu, 18 Dec 2025 20:36:26 +0000_  
  The FDA placed a partial hold on Daiichi Sankyo and Merck’s Phase 3 study of a lung cancer drug after the companies paused enrollment for what they called a "higher than anticipated incidence" of deaths ...

- **[Endpoints biopharma sentiment survey for Q1 2026](https://endpoints.news/endpoints-biopharma-sentiment-survey-for-q1-2026/)**  
  _Thu, 18 Dec 2025 18:54:39 +0000_  
  We're conducting a 3-minute survey that tracks the mood across the industry — science, finance, hiring and regulation

- **[AI startup Edison raises $70M seed for research software](https://endpoints.news/ai-startup-edison-raises-70m-seed-for-research-software/)**  
  _Thu, 18 Dec 2025 17:51:57 +0000_  
  The new for-profit spinoff from the AI research group FutureHouse has raised a $70 million seed round, the latest funding behind the nascent idea of autonomous science.

 San Francisco-based Edison Scientific said Thursday it plans ...

- **[After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset](https://endpoints.news/after-year-of-triumph-insmed-stumbles-with-chronic-rhinosinusitis-fail-brings-in-new-asset/)**  
  _Thu, 18 Dec 2025 16:35:36 +0000_  
  Insmed said it is discontinuing work on Brinsupri in a form of chronic rhinosinusitis after the inflammation drug failed a Phase 2b study.

 The Bridgewater, NJ-based biotech also said Wednesday it's bringing in an old ...

- **[Biopharma's winners and losers of 2025](https://endpoints.news/biopharmas-winners-and-losers-of-2025/)**  
  _Thu, 18 Dec 2025 16:20:28 +0000_  
  What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our

- **[Takeda's $4B immunology drug achieves first Phase 3 successes](https://endpoints.news/takedas-4b-immunology-drug-achieves-first-phase-3-successes/)**  
  _Thu, 18 Dec 2025 15:58:06 +0000_  
  Early returns suggest that Takeda’s $4 billion immunology bet appears to be paying off.

 Takeda said Thursday that its drug zasocitinib succeeded in two Phase 3 studies for plaque psoriasis, comparing ...

- **[Alnylam, INCOG and Novartis expand in US; Ember gets $16.5M Series A](https://endpoints.news/alnylam-incog-and-novartis-expand-in-us-ember-gets-16-5m-series-a/)**  
  _Thu, 18 Dec 2025 14:57:00 +0000_  
  Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 Alnylam Pharmaceuticals is spending $250 million to expand its factory in Norton ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-pfizer-rna-leader-runs-replicate" hreflang="en">Chutes &amp; Ladders—Pfizer RNA leader runs to Replicate</a>](https://www.fiercebiotech.com/biotech/chutes-ladders-pfizer-rna-leader-runs-replicate)**  
  _Dec 18, 2025 5:17pm_  
  Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big Pharma behind to take on the role of chief business officer at San Diego biotech Replicate Bioscience. There, she’ll work to advance Replicate’s early-stage pipeline of assets built on self-replicating RNA technology.

- **[<a href="https://www.fiercebiotech.com/biotech/altimmune-eyes-phase-3-mash-trial-weight-loss-deepens" hreflang="en">Altimmune eyes phase 3 MASH trial as weight loss deepens</a>](https://www.fiercebiotech.com/biotech/altimmune-eyes-phase-3-mash-trial-weight-loss-deepens)**  
  _Dec 19, 2025 8:16am_  
  Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual receptor agonist to continued weight loss and improvements on noninvasive measures of liver fibrosis.

- **[<a href="https://www.fiercebiotech.com/biotech/boehringer-walks-away-nxeras-phase-2-ready-schizophrenia-program" hreflang="en">Boehringer walks away from Nxera's phase 2-ready schizophrenia program</a>](https://www.fiercebiotech.com/biotech/boehringer-walks-away-nxeras-phase-2-ready-schizophrenia-program)**  
  _Dec 19, 2025 4:43am_  
  Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment.

- **[<a href="https://www.fiercebiotech.com/biotech/karuna-head-teva-alums-meet-minds-launch-schizophrenia-focused-biotech-syremis-165m-series" hreflang="en">Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A</a>](https://www.fiercebiotech.com/biotech/karuna-head-teva-alums-meet-minds-launch-schizophrenia-focused-biotech-syremis-165m-series)**  
  _Dec 18, 2025 11:01am_  
  Founded by a team of neuropsychiatric-focused Teva alums and the force behind Cobenfy maker Karuna, Syremis Therapeutics is off to the races with a $165 million series A to support the development of a dual M1/M4 agonist in schizophrenia.

- **[<a href="https://www.fiercebiotech.com/biotech/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program" hreflang="en">Patient deaths prompt partial hold for Daiichi-Merck’s global phase 3 ADC program  </a>](https://www.fiercebiotech.com/biotech/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program)**  
  _Dec 18, 2025 11:02am_  
  Daiichi Sankyo and Merck & Co.’s phase 3 program for their investigational antibody-drug conjugate has been hit with a hold after an unexpected number of deaths were reported in the global trial.

- **[<a href="https://www.fiercebiotech.com/medtech/ai-drug-designer-insilico-medicine-aims-generate-300m-hong-kong-ipo" hreflang="en">AI drug designer Insilico Medicine aims to generate nearly $300M in Hong Kong IPO</a>](https://www.fiercebiotech.com/medtech/ai-drug-designer-insilico-medicine-aims-generate-300m-hong-kong-ipo)**  
  _Dec 18, 2025 10:59am_  
  The IPO filing wraps up a year that saw Insilico raise $110 million in venture capital and sign multiple R&D deals with global drugmakers.

- **[<a href="https://www.fiercebiotech.com/biotech/athira-inks-sermonix-deal-power-ex-pfizer-asset-toward-phase-3-breast-cancer-data" hreflang="en">Athira inks Sermonix deal to power ex-Pfizer asset toward phase 3 breast cancer data</a>](https://www.fiercebiotech.com/biotech/athira-inks-sermonix-deal-power-ex-pfizer-asset-toward-phase-3-breast-cancer-data)**  
  _Dec 18, 2025 10:57am_  
  Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

- **[<a href="https://www.fiercebiotech.com/biotech/after-hhs-funding-was-scrapped-cepi-fronts-54m-carry-modernas-pandemic-influenza-vaccine-ph" hreflang="en">After HHS funding was scrapped, CEPI fronts up to $54M to carry Moderna's pandemic influenza vaccine into phase 3</a>](https://www.fiercebiotech.com/biotech/after-hhs-funding-was-scrapped-cepi-fronts-54m-carry-modernas-pandemic-influenza-vaccine-ph)**  
  _Dec 18, 2025 9:09am_  
  The Coalition for Epidemic Preparedness Innovations—already engaged in a strategic partnership with Moderna—has agreed to plug up to $54.3 million into a pivotal phase 3 trial for mRNA-1018, Moderna’s mRNA-based H5 pandemic influenza vaccine candidate.

- **[<a href="https://www.fiercebiotech.com/cro/lindus-health-and-quotient-team-create-one-stop-shop-early-midstage-trials" hreflang="en">Lindus Health and Quotient team up to create one-stop shop for early- to midstage trials</a>](https://www.fiercebiotech.com/cro/lindus-health-and-quotient-team-create-one-stop-shop-early-midstage-trials)**  
  _Dec 17, 2025 2:36pm_  
  Clinical development accelerator Quotient Sciences and CRO Lindus Health are joining forces to create a streamlined process for clients to advance from first-in-human (FIH) to pivotal trials.

- **[<a href="https://www.fiercebiotech.com/biotech/fired-nih-institute-director-sues-trump-health-officials-calling-ouster-illegal" hreflang="en">Fired NIH institute director sues Trump health officials, seeks reinstatement and back pay</a>](https://www.fiercebiotech.com/biotech/fired-nih-institute-director-sues-trump-health-officials-calling-ouster-illegal)**  
  _Dec 17, 2025 12:29pm_  
  The former director of the National Institutes of Health’s National Institute of Allergy and Infectious Diseases is suing Trump administration officials over her September firing, which she alleges violated her rights and was illegal under federal whistleblower protections.

- **[<a href="https://www.fiercebiotech.com/biotech/norgine-gets-virs-hepatitis-d-program-eu550-european-licensing-pact" hreflang="en">Norgine gets in on Vir's hepatitis D program with €550M European licensing pact</a>](https://www.fiercebiotech.com/biotech/norgine-gets-virs-hepatitis-d-program-eu550-european-licensing-pact)**  
  _Dec 17, 2025 11:18am_  
  Norgine secured an exclusive license to commercialize Vir Biotechnology's combo hepatitis D prospect of tobevibart and elebsiran in Europe, Australia and New Zealand.


## MHRA – News

- **[Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2025 to 2026](https://www.gov.uk/government/publications/medicines-and-healthcare-products-regulatory-agency-spending-over-25000-2025-to-2026)**  
  _2025-12-19T09:58:19Z_  
  Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.

- **[Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2025-26](https://www.gov.uk/government/publications/medicines-and-healthcare-products-regulatory-agency-gpc-spending-over-500-2025-26)**  
  _2025-12-19T09:50:19Z_  
  MHRA transactions over £500 made using the government procurement card (GPC).


## arXiv q-bio

- **[Enzyme-Substrate Complex Formation Modulates Diffusion-Driven Patterning In Metabolic Pathways](https://arxiv.org/abs/2512.15737)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15737v1 Announce Type: new 
Abstract: We investigate how enzymatic binding kinetics regulate diffusion-driven instabilities in a two-step metabolic pathway. Starting from a mechanistic description in which the substrate reversibly binds to the first enzyme before catalytic conversion, we formulate two react…

- **[Foundation Models in Biomedical Imaging: Turning Hype into Reality](https://arxiv.org/abs/2512.15808)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15808v1 Announce Type: new 
Abstract: Foundation models (FMs) are driving a prominent shift in artificial intelligence across different domains, including biomedical imaging. These models are designed to move beyond narrow pattern recognition towards emulating sophisticated clinical reasoning, understanding…

- **[Accessibility of Modified NK Fitness Landscapes](https://arxiv.org/abs/2512.15828)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15828v1 Announce Type: new 
Abstract: In this paper we present two modifications of traditional $NK$ fitness landscapes, the $\theta NK$ and $HNK$ models, and explore these modifications via accessibility and ruggedness. The $\theta NK$ model introduces a parameter $\theta$ to integrate local Rough Mount Fu…

- **[Handling Class Imbalance Problem in Skin Lesion Classification: Finding Strengths and Weaknesses of Various Balancing Techniques](https://arxiv.org/abs/2512.15837)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15837v1 Announce Type: new 
Abstract: Automatic skin lesion classification from dermoscopy images is important for the early diagnosis of skin diseases such as melanoma. Class imbalance in skin lesion datasets, notably the defects in the representation of malignant(cancerous) cases, is one of the difficulti…

- **[Dynamical Mechanisms for Coordinating Long-term Working Memory Based on the Precision of Spike-timing in Cortical Neurons](https://arxiv.org/abs/2512.15891)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15891v1 Announce Type: new 
Abstract: In the last century, most sensorimotor studies of cortical neurons relied on average firing rates. Rate coding is efficient for fast sensorimotor processing that occurs within a few seconds. Much less is known about long-term working memory with a time scale of hours (E…

- **[Scalable Agentic Reasoning for Designing Biologics Targeting Intrinsically Disordered Proteins](https://arxiv.org/abs/2512.15930)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15930v1 Announce Type: new 
Abstract: Intrinsically disordered proteins (IDPs) represent crucial therapeutic targets due to their significant role in disease -- approximately 80\% of cancer-related proteins contain long disordered regions -- but their lack of stable secondary/tertiary structures makes them…

- **[Lifting Biomolecular Data Acquisition](https://arxiv.org/abs/2512.15984)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.15984v1 Announce Type: new 
Abstract: One strategy to scale up ML-driven science is to increase wet lab experiments' information density. We present a method based on a neural extension of compressed sensing to function space. We measure the activity of multiple different molecules simultaneously, rather th…

- **[retinalysis-fundusprep: A python package for robust color fundus image bounds extraction](https://arxiv.org/abs/2512.16044)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.16044v1 Announce Type: new 
Abstract: Color fundus image (CFI) bounds detection and contrast enhancement are fundamental tasks in automatic CFI analysis. We present an open-source algorithm, published as a Python package, to automatically extract parametric bounds from color fundus images, and for applying…

- **[Can plants grow on the Moon and Mars: seed germination enhancement using magnesium oxide coated halloysite nanotubes (MgO HNTs)](https://arxiv.org/abs/2512.16084)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2512.16084v1 Announce Type: new 
Abstract: This study examines the application of metal coated nanotubes, specifically magnesium oxide coated halloysite nanotubes (MgO HNTs), to enhance seed germination and early plant development under Earth, lunar, and Martian soil conditions. MgO HNTs were synthesized through…

- **[Artificial Intelligence for Microbiology and Microbiome Research](https://arxiv.org/abs/2411.01098)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2411.01098v2 Announce Type: replace 
Abstract: Advancements in artificial intelligence (AI) have transformed many scientific fields, with microbiology and microbiome research now experiencing significant breakthroughs through machine learning applications. This review provides a comprehensive overview of AI-driv…

- **[Retrieval-Augmented Generation in Biomedicine: A Survey of Technologies, Datasets, and Clinical Applications](https://arxiv.org/abs/2505.01146)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2505.01146v4 Announce Type: replace 
Abstract: Large language models (LLMs) in biomedicine face a fundamental conflict between static parameter knowledge and the dynamic nature of clinical evidence. Retrieval-Augmented Generation (RAG) addresses this by grounding generation in external data, yet it introduces ne…

- **[Determining disease attributes from epidemic trajectories](https://arxiv.org/abs/2507.22087)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2507.22087v2 Announce Type: replace 
Abstract: Effective public health decisions require early reliable inference of infectious disease properties. In this paper we assess the ability to infer infectious disease attributes from population-level stochastic epidemic trajectories. In particular, we construct stocha…

- **[Unsupervised discovery of the shared and private geometry in multi-view data](https://arxiv.org/abs/2408.12091)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2408.12091v3 Announce Type: replace-cross 
Abstract: Studying complex real-world phenomena often involves data from multiple views (e.g. sensor modalities or brain regions), each capturing different aspects of the underlying system. Within neuroscience, there is growing interest in large-scale simultaneous recor…

- **[Knowledge-Driven Agentic Scientific Corpus Distillation Framework for Biomedical Large Language Models Training](https://arxiv.org/abs/2504.19565)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2504.19565v3 Announce Type: replace-cross 
Abstract: Corpus distillation for biomedical large language models (LLMs) seeks to address the pressing challenge of insufficient quantity and quality in open-source annotated scientific corpora, which remains a bottleneck for effective LLM training in biomedical resear…

- **[Scientific Machine Learning of Chaotic Systems Discovers Governing Equations for Neural Populations](https://arxiv.org/abs/2507.03631)**  
  _Fri, 19 Dec 2025 00:00:00 -0500_  
  arXiv:2507.03631v3 Announce Type: replace-cross 
Abstract: Discovering governing equations that describe complex chaotic systems remains a fundamental challenge in physics and neuroscience. Here, we introduce the PEM-UDE method, which combines the prediction-error method with universal differential equations to extrac…
